The assessment of the new immune gene signature (CD2, CD3D, CD3E, and CXCRC6) in the CSCC cohort per tumor stage was not possible because sample size was too low for a meaningful analysis when we filtered data by stage. The gene discussed is CD3D; the disease is neoplasm.